Alzheimer’s Researchers Identify Biomarkers of Response to Anavex 2-73 Treatment

Alzheimer’s Researchers Identify Biomarkers of Response to Anavex 2-73 Treatment
Researchers have identified two biomarkers that could help determine which Alzheimer’s disease patients can benefit from Anavex 2-73 treatment. The results were reported at the 2018 Alzheimer’s Association International Conference (AAIC) in Chicago. The study, “Systematic Processing of Full Genomic Analysis of ANAVEX®2-73 Phase 2a Alzheimer’s Disease Study Identifies Biomarkers Enabling a Precision Medicine Approach,” was presented

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *